Hematotoxicity after Radioligand Therapy with 177Lu-PSMA-617 in Patients with Metastastic Prostate Cancer

被引：0
作者：
Groener, Daniel [1 ]
Baumgarten, Justus [1 ]
Davis, Karen [1 ]
Happel, Christian [1 ]
Ngoc, Christina Nguyen [1 ]
Wichert, Jennifer [1 ]
Mader, Nicolai [1 ]
Mandel, Philipp [2 ]
Nikolaos, Tselis [3 ]
Gruenwald, Frank [1 ]
Sabet, Amir [1 ]
机构：
[1] Univ Hosp Frankfurt, Nucl Med, Frankfurt, Germany
[2] Univ Hosp Frankfurt, Urol, Frankfurt, Germany
[3] Univ Hosp Frankfurt, Radiat Oncol, Frankfurt, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2020年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
594
引用
收藏
页数：1
相关论文
共 50 条
[21]   Myelotoxicity after Treatment with 177Lu-PSMA-617 in Patients with Metastatic Prostate Cancer [J].
Groener, D. ;
Baumgarten, J. ;
Davis, K. ;
Happel, C. ;
Mader, N. ;
Ngoc, C. Nguyen ;
Wichert, J. ;
Mandel, P. ;
Tselis, N. ;
Gruenwald, F. ;
Sabet, A. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) :S694-S695
[22]   Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617 [J].
Ferdinandus, Justin ;
Eppard, Elisabeth ;
Gaertner, Florian C. ;
Kuerpig, Stefan ;
Fimmers, Rolf ;
Yordanova, Anna ;
Hauser, Stefan ;
Feldmann, Georg ;
Essler, Markus ;
Ahmadzadehfar, Hojjat .
JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (02) :312-319
[23]   Nephro- and hepatotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617 [J].
Becker, Anja ;
Eppard, Elisabeth ;
Kuerpig, Stefan ;
Fisang, Christian ;
Yordanova, Anna ;
Essler, Markus ;
Ahmadzadehfar, Hojjat .
JOURNAL OF NUCLEAR MEDICINE, 2016, 57
[24]   177Lu-PSMA-617 for metastatic prostate cancer in India [J].
Ghose, Aruni ;
Banerjee, Soirindhri ;
Choudhury, Partha S. ;
Maniam, Akash ;
Gupta, Manoj ;
Banna, Giuseppe L. ;
Vasdev, Nikhil ;
Ghose, Amit ;
Noronha, Vanita ;
Mitra, Swarupa .
LANCET REGIONAL HEALTH - SOUTHEAST ASIA, 2024, 30
[25]   177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response [J].
Rahbar, Kambiz ;
Boegemann, Martin ;
Ahmadzadehfar, Hojjat .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) :166-167
[26]   Radiobiological parameters for the assessment of 177Lu-PSMA-617 Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer [J].
Hu, J. ;
Xue, S. ;
Mercolli, L. ;
Sari, H. ;
Rominger, A. ;
Afshar-Oromieh, A. ;
Shi, K. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) :S636-S636
[27]   Therapeutic response and safety of radioligand therapy with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients [J].
Ashfaq, Wardah ;
Rehman, Khurram ;
Shahid, Abubaker ;
Younis, Muhammad Numair .
MEDICAL ONCOLOGY, 2024, 41 (09)
[28]   177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney [J].
Zhang, Jingjing ;
Kulkarni, Harshad R. ;
Singh, Aviral ;
Schuchardt, Christiane ;
Niepsch, Karin ;
Langbein, Thomas ;
Baum, Richard P. .
JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (11) :1579-1586
[29]   177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response [J].
Kambiz Rahbar ;
Martin Bögemann ;
Hojjat Ahmadzadehfar .
European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 :166-167
[30]   177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney [J].
Zhang, Jingjing ;
Kulkarni, Harshad ;
Singh, Aviral ;
Schuchardt, Christiane ;
Niepsch, Karin ;
Langbein, Thomas ;
Baum, Richard .
JOURNAL OF NUCLEAR MEDICINE, 2019, 60
12345